Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A. Beck, Arsalan Shabbir, Ryszard Galus et al.|American Journal of Clinical Dermatology|2022Cited by 104
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial dataAmy S. Paller, Sonya Cyr, Lisa A. Beck et al.|Pediatric Dermatology|2022Cited by 46